{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:13:24Z","timestamp":1790766804965,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The phase III SOLO2 global study demonstrated the efficacy and safety of maintenance olaparib, a poly(adenosine diphosphate\u2010ribose) polymerase inhibitor, in platinum\u2010sensitive relapsed ovarian cancer patients with a BRCA mutation. This separate China cohort of SOLO2 investigated the efficacy and safety of maintenance olaparib in Chinese patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients received olaparib (300\u00a0mg twice daily, oral, tablets) or matched placebo. Primary endpoint was investigator\u2010assessed progression\u2010free survival (Response Evaluation Criteria in Solid Tumors version 1.1). Safety and tolerability were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010two patients were treated. Olaparib treatment led to an improvement in progression\u2010free survival compared with placebo (hazard ratio\u00a0=\u00a00.44, 95% confidence interval: 0.17\u20131.19; median\u00a0=\u00a013.8 vs. 5.5\u00a0months). Results of secondary efficacy endpoints of time to first subsequent treatment\/death and time to treatment discontinuation\/death were consistent with progression\u2010free survival results. Time to second progression\/death and time to second subsequent treatment\/death data were immature at data cutoff. The most common adverse events in the olaparib arm were nausea (81.8%), anemia (45.5%), and decreased appetite (36.4%). Grade \u22653 adverse events were experienced by 36.4% of olaparib and 10.0% of placebo patients. No adverse events led to discontinuation of treatment. There were six deaths (olaparib, five; placebo, one); one death in the olaparib arm was due to an unknown cause, all others were related to disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Efficacy and safety findings in the China SOLO2 cohort support the use of olaparib (300\u00a0mg twice daily) as maintenance treatment for Chinese patients with platinum\u2010sensitive relapsed ovarian cancer and a BRCA mutation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13753","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:25:31Z","timestamp":1648725931000},"page":"714-722","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Olaparib maintenance monotherapy in Chinese patients with platinum\u2010sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial"],"prefix":"10.1111","volume":"18","author":[{"given":"Jihong","family":"Liu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China Sun Yat\u2010sen University Cancer Center  Guangzhou China"},{"name":"Department of Gynecologic Oncology Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, West China Second University Hospital Sichuan University  Chengdu China"},{"name":"Key Laboratory of Obstetrics &amp; Gynecologic and Pediatric Diseases and Birth Defects of the Ministry of Education, West China Second University Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Hospital Chinese Academy of Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology Harbin Medical University Cancer Hospital  Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Chongqing Cancer Hospital  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunong","family":"Gao","sequence":"additional","affiliation":[{"name":"Beijing Cancer Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Hospital of Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youguo","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Jilin Cancer Hospital  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueling","family":"Wang","sequence":"additional","affiliation":[{"name":"No. 1 Affiliated Hospital of Medical School Xi'an Jiaotong University  Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Lu","sequence":"additional","affiliation":[{"name":"Women's Hospital School of Medicine Zhejiang University  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Center The First Hospital of Jilin University  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[{"name":"AstraZeneca  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hsu","sequence":"additional","affiliation":[{"name":"Celgene  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.02.017"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0511-373"},{"key":"e_1_2_10_6_1","unstructured":"AstraZenecaLynparza summary of product characteristics. Accessed November 9 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lynparza\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_7_1","unstructured":"AstraZenecaLYNPARZA\u00ae (olaparib) tablets for oral use: prescribing information. Accessed November 9 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208558s019s020lbl.pdf"},{"key":"e_1_2_10_8_1","unstructured":"AstraZenecaLynparza receives approval in Japan for the treatment of advanced ovarian cancer. Accessed May 29 2020.https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/lynparza-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer-19012018.html#"},{"key":"e_1_2_10_9_1","unstructured":"BioCentury IncChina approves Lynparza in ovarian cancer. Accessed May 29 2020.https:\/\/www.biocentury.com\/article\/297563\/china\u2010approves\u2010lynparza\u2010in\u2010ovarian\u2010cancer"},{"key":"e_1_2_10_10_1","unstructured":"AstraZenecaLynparza approved in Japan for 1st\u2010line maintenance therapy in BRCA\u2010mutated advanced ovarian cancer. Accessed May 29 2020.https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-19062019.html#"},{"key":"e_1_2_10_11_1","unstructured":"AstraZenecaLynparza approved in China as a 1st\u2010line maintenance therapy in BRCA\u2010mutated advanced ovarian cancer. Accessed December 16 2019.https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer.html#"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70228-1"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_2_10_15_1","unstructured":"European Medicines Agency. ICH topic E6(R1): Guideline for good clinical practiceInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (July). Accessed May 29 2020.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010e6\u2010r1\u2010guideline\u2010good\u2010clinical\u2010practice_en.pdf"},{"key":"e_1_2_10_16_1","unstructured":"AstraZenecaAstraZeneca: global policy: bioethics. Accessed June 15 2020.https:\/\/www.astrazeneca.com\/content\/dam\/az\/our\u2010company\/Documents\/Bioethics\u2010Policy.pdf"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0271-y"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03799-1"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13753","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:20:55Z","timestamp":1692649255000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/ajco.13753"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13753","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"2021-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}